ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Philips highest ranked medical technology company among Clarivate Top 100 Global Innovators

March 12, 2025

Amsterdam, the Netherlands – 
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in the Top 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years.

Roy Jakobs, CEO of Royal Philips said: "At Philips, we’ve been innovating for over 130 years to improve people’s lives. Innovation is our fundamental strength, the reason why customers choose us as their strategic partner and a key value driver for our company. Our portfolio of patient- and people-centric innovations in hardware, software, AI and services drives healthcare productivity and empowers people to look after their health and well-being – delivering better care for more people."

In 2024, Philips invested approximately EUR 1.7 billion – or an industry leading >9% of sales – in research and development to help drive better care for more people. Philips is increasingly focusing its innovation efforts on the potential of data and AI, both in hospital settings and at home. As a leader in AI-related patent applications in healthcare, Philips dedicates around half of its R&D workforce to these fields. 

Examples of Philips’ AI-powered innovations that increase caregiver productivity and deliver better care for more people include:

  • the Philips CT 5300, which combines innovative hardware, software, and AI to make high-quality screening, diagnostic, and interventional imaging accessible to more patients
  • the latest SmartSpeed Precise MRI technology, which enables scans to be completed up to three times faster, significantly cutting scan times while maintaining exceptional image quality
  • the next-generation AI-enabled cardiovascular ultrasound platform with advanced AI tools to advance cardiovascular imaging and increase automation and productivity
  • the new Azurion image-guided therapy system and advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients 


The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. The full report can be found here.


For further information, please contact:


Ben Zwirs
Philips Global External Relations
Tel.: +31 61521 3446
E-mail: media@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.25
+2.28 (1.00%)
AAPL  269.00
+0.19 (0.07%)
AMD  258.01
-1.66 (-0.64%)
BAC  52.87
-0.15 (-0.28%)
GOOG  268.43
-1.50 (-0.56%)
META  751.44
+0.62 (0.08%)
MSFT  542.07
+10.55 (1.98%)
NVDA  201.03
+9.54 (4.98%)
ORCL  280.83
-0.57 (-0.20%)
TSLA  460.55
+8.13 (1.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.